Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review
Marcell Csanádi(Syreon Research Institute (Hungary)), Jonas Mattsson(University Health Network), Tamás Ágh(Syreon Research Institute (Hungary)), Jeremiah Trudeau(Janssen (United States)), Christoph Tapprich(Johnson & Johnson (Germany)), Szabolcs Farkas-Ráduly, Blanca Gros, Jeffrey H. Lipton(Princess Margaret Cancer Centre)
Cited by 0
Related Papers
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92
Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings
|Bone Marrow Transplantation|2005|81
Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning
|Biology of Blood and Marrow Transplantation|2014|67